ClinicalTrials.gg
RecruitingNCT07732634RiMO-HNC-NEO1Updated Nov 16, 2026

Phase 2 Study of RiMO-301 for the Neoadjuvant Treatment of Resectable, Locally Advanced Head-Neck Cancer

A Phase 2 interventional study of RiMO-301 and Pembrolizumab in Head and Neck Cancer, Head Cancer and Neck Cancer, sponsored by University of Illinois Chicago. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by University of Illinois Chicago · Phase 2, Interventional, and Treatment

How we know · 10 judgments

Updated Nov 16, 2026Now RecruitingSite recruiting status changed+8 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,317 studies in Head and Neck Neoplasms with a site in United States — 187 open to participants now, 283 under way, 15 of them phase 3. Head and Neck Neoplasms · United States.

Planned enrollment
733rd of 1,073
20 · median 36
Started
2026
with 57 others
Phase 2
354 of 1,317
42 open now
Primary completion
2029-11
later than 239 of 282 live
Registered
1,294th of 1,317
by date

Among the 1,317 studies in Head and Neck Neoplasms with a site in United States, this one is the 733rd largest by planned enrollment of the 1,073 interventional ones that give a count, is one of 58 that started in 2026, is one of 354 in phase 2, reaches primary completion later than 239 of the 282 other live ones, and was the 1,294th registered.

Head and Neck Neoplasms

2,718 studies on the registry are indexed under Head and Neck Neoplasms; 599 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

187 of the 1,317 studies in Head and Neck Neoplasms with a site in United States are open now. Recruiting first, the newest first:

181 more — sign in →

All 187 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 458 Head and Neck Neoplasms studies recruiting now, 350 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,317 studies in Head and Neck Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The primary objective is to evaluate major pathologic response after RiMO-301 with hypofractionated radiotherapy and a PD-1 inhibitor (pembrolizumab). The secondary objectives include determining event-free survival for up to 12 months and overall survival for up to 24 months.

Read the detailed description

RiMO-301 is administered intratumorally once prior to radiotherapy, with or without ultrasound/computed tomography (CT) guidance. Radiotherapy (RT) is given starting within 1 day after RiMO-301 injection for 5 fractions of (4-5) Gray per fraction over a period of 5-15 days. PD-1 inhibitor pembrolizumab will be administered via 30-minute intravenous infusion, respectively, 200 mg once every three weeks (Q3W) with the first dose on the same day as RiMO-301 injection (+/- 1 day) for two cycles. Assessment of response will be clinically confirmed with CT imaging studies performed 5 weeks after the last radiation and pathology evaluation of the resected tumor. Event-free survival will be clinically evaluated every three months up to 12 months, CT imaging studies will be performed every 6 months after surgery up to 12 months after surgery, and overall survival will be clinically evaluated up to two years.

03

Conditions studied

  • Head and Neck Cancer
  • Head Cancer
  • Neck Cancer
04

Who can participate

The criteria were revised on the registry on Nov 16, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of head and neck cancer that requires surgical resection
  • Must have at least one lesion that is clinically accessible to RiMO-301 injection and amenable to receiving hypofractionated radiotherapy
  • The selected target lesions must be measurable on cross-sectional imaging, and repeated measurements at the same location should be achievable
  • Target tumor not in the previously irradiated field or in the field irradiated at least six months prior to RiMO-301 injection, and with no complications from the prior radiation course
  • Patients must have recovered from acute toxic effects (≤ grade 1 CTCAEv6) of previous cancer treatments prior to enrollment
  • Patients with locally advanced, resectable head and neck cancer:

    • suitable to receive a inhibitor (pembrolizumab) as a standard of care in the discretion of the treating physician or Principal Investigator
    • suitable to receive hypofractionated radiotherapy as a standard of care in the discretion of the treating physician or Principal Investigator
  • Have adequate bone marrow reserve:

    • ≥1.5x10\^9 cell/L
    • count ≥100x10\^9 cell/L
    • at least ≥9.0 g/dL unless confirmed by treating physician as not posing any increased harm to patient and approved by Sponsor (transfusion is allowed to achieve hemoglobin of ≥9.0 g/dL 14-days prior to dosing)
  • Have adequate liver function:

    • Total serum no more than 1.5x (ULN)
    • (ALT) and aspartate aminotransferase (AST) ≤2.5x ULN or ≤5.0x ULN in case of documented hepatic
    • Alkaline phosphatase ≤5x ULN
  • Have a of at least 12 weeks (in the opinion of the investigator)
  • (ECOG) performance status 0-2
  • Females with should be using adequate measures from the time of screening until 6 months after study discontinuation, should not be breastfeeding, and must have a negative pregnancy test prior to start of dosing
  • Patients must sign a study-specific form prior to study entry.

Exclusion criteria

Exclusion Criteria:

* Diagnosis other than resectable, locally advanced head and neck cancers

  • HPV associated head and neck cancer
  • Nasopharynx head and neck cancer
  • Have signs or symptoms of end-stage failure, major chronic illnesses other than cancer, or any severe concomitant conditions
  • Symptomatic central nervous system and/or carcinomatous meningitis
  • Has received any approved or anti-neoplastic agent or immunotherapy other than inhibitors, pembrolizumab, within 4 weeks prior to RiMO-301 injection.
  • Patients who are intolerant to pembrolizumab
  • Active disease that has required systemic treatment in the past 2 years
  • Ongoing infection at or near the incident lesion
  • Major surgery over the target area (excluding placement of vascular access) ≤21 days from the beginning of the study drug or minor surgical procedures ≤7 days. No waiting is required following implantable port, enteral feeding tube, and catheter placement
  • Other severe acute or chronic medical or psychiatric conditions or laboratory abnormality that would make the patient inappropriate for enrollment in this study
  • Has any mental or medical condition that prevents the patient from giving or participating in the trial
  • Pregnant and nursing women are excluded because of the potential teratogenic effects and potential unknown effects on nursing newborns
  • Patients with a target lesion in the field that had complications from prior radiotherapy that are not amenable to repeat irradiation in the discretion of the treating physician or Principal Investigator
  • Patients with lesions that have significant blood vessel involvement (such as carotid artery encasement) or other major structures
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    RiMO-301 combined with radiotherapy and pembrolizumab followed by surgical resection

    RiMO-301 will be injected intratumorally once prior to radiotherapy. Radiotherapy will start within 1 day after the RiMO-301 injection for 5 fractions of 4-5 Grays per fraction over a period of 5-15 days. Pembrolizumab 200 mg will be administered intravenously every 3 weeks (Q3W) within the first dose given on the same day as the RiMO-301 injection (+/-1 day). Pembrolizumab will continue for 2 cycles (1 cycle = 21 days). Surgical resection of the tumor will occur after the completion of neoadjuvant therapy.

    Drug: RiMO-301 · Drug: Pembrolizumab · Radiation: Radiation · Procedure: Surgical resection

Interventions

  • DrugMOF Compound RiMO-301Studies of MOF Compound RiMO-301MOF Compound RiMO-301 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    RiMO-301 will be dosed on Day 0 prior to radiotherapy. The injection point will be as closed to half of the tumor depth as possible.

  • Pembrolizumab will be administered at 200 mg once every 3 weeks (Q3W) with the first dose on Day 0 +/- 1 day. Pembrolizumab will be given for a total of two cycles prior to surgery.

    Also known as: Keytruda

  • RadiationRadiation

    Hypofractionated radiation will will be given within 1 day after RiMO-301 injection and will continue over a period of 5-15 days. Participants will be receive 5 fractions of radiation with a dose of 4-5 Gray per fraction.

  • ProcedureSurgical resection

    Surgical resection of the tumor will occur following neoadjuvant therapy.

06

What researchers measure

Primary outcomes

  1. Efficacy of RiMO-301 when used in combination with radiotherapy and pembrolizumab as defined by major pathologic response (i.e., percentage of participants whose tumors shrink).

    The rate of Major Pathological Response will be defined as the proportion of participants undergoing post-neoadjuvant treatment surgical resection who are found to have no more than 10% of residual invasive cancer cells present in the collected tumor specimen

    Time frame: At surgical resection

Secondary outcomes

  1. Progression-free survival rate as defined by the number of patients whose disease progresses since the start of treatment

    itRECIST criteria will be used to assess progression free survival rate

    Time frame: Treatment start until 12 months after the start of treatment

  2. Overall survival rate as defined by the number of deaths among participants

    Overall survival rate will be calculated based on the number of deaths

    Time frame: Treatment start until 24 months after the start of treatment

  3. Number of Grade 3 and Grade 4 toxicities experienced by participants as defined by CTCAE version 6

    CTCAE version 6 will be used to assess toxicities that are experienced

    Time frame: Treatment start until 5 weeks after the last dose of radiation therapy (that is, approximately 7 weeks after treatment start)

  4. To assess the rate of Pathological Complete Response (pCR)

    The rate of Pathological Complete Response will be defined as the proportion of participants undergoing post-neoadjuvant treatment surgical resection with no residual invasive cancer within the resected primary tumor and sampled regional lymph nodes

    Time frame: At surgical resection

  5. To assess surgical outcomes through margin measurements at surgical resection

    Surgical outcomes will be assessed through margin measurements, specifically the proportion of participants who have positive surgical margins (that is, presence of invasive tumor front at resected margin) and the proportion of people who have close surgical margins (that is, the presence of invasive tumor front \<2-5 mm from the resected margin)

    Time frame: At surgical resection

  6. To evaluate the change in disease staging as assessed by the proportion of patients who have a reduction in the size or extent of tumor

    Tumor downstaging will be assessed by imaging and clinical staging by T or N status

    Time frame: Pre-treatment until 12 months after the start of treatment

07

Study locations

1 of 1 sites recruiting
  • University of Illinois at Chicago
    Chicago, Illinois 60612, United States
    Recruiting
    • Ameen Salahudeen, MD, PhD · Contactameen@uic.edu · (312) 355-1625
    • Ameen Salahudeen, MD, PhD · Principal investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2026 (actual). Primary completion is estimated for Nov 2029, 36 months after the start.

Of 219 non-industry phase 2 interventional studies under Head and Neck Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 84. This study's planned 36 months is below that.

Counting every sponsor, half of 263 studies reached it within 51 months; a quarter within 30 and three quarters within 76.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: start Aug 2026 → Nov 2026, primary completion Aug 2029 → Nov 2029 and completion Aug 2031 → Nov 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2026
First posted
Jul 29, 2026
StartActual
Nov 9, 2026was Aug 2026
Primary completionEst.
Nov 2029was Aug 2029
CompletionEst.
Nov 2031was Aug 2031
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 16, 2026
Sites
University of Illinois at Chicago is now Recruiting
Nov 16, 2026
Start date
Aug 2026→Nov 9, 2026 (actual)
Nov 16, 2026
Primary completion
Aug 2029→Nov 2029
Nov 16, 2026
Study completion
Aug 2031→Nov 2031
Nov 16, 2026
Eligibility
2 inclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedAbsolute neutrophil count ≥1.5x1095x10\^9 cell/L
  • EditedPlatelet count ≥100x109100x10\^9 cell/L
Nov 16, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedEfficacy of RiMO-301 when used in combination with radiotherapy and pembrolizumab as defined by clinicalmajor pathologic response rate (i.e., percentage of participants whose tumors shrink).Time frame: Treatment start until 12 months after the start of treatment → At surgical resection
Nov 16, 2026
Secondary outcomes
1 removed, 1 description edited
What changed in the outcomes
  • RemovedTo assess the rate of Major Pathological Response (MPR)Time frame: At surgical resection
  • DescriptionProgression-free survival rate as defined by the number of patients whose disease progresses since the start of treatment: how it is measured was reworded
Nov 16, 2026
Contact
Study contact changed: j•••@uic.edu · •••1469→m•••@uic.edu · •••5112. See the current contact
Nov 16, 2026
Title
RiMO-HNC-NEO1: Phase 2 Study of RiMO-301 and Hypofractionated Radiotherapy With Pembrolizumab for the Neoadjuvant Treatment of Resectable, Locally Advanced Head-Neck Cancer
Nov 16, 2026
Sponsor
University of Illinois at Chicago→University of Illinois Chicago
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Not yet recruiting→Recruiting
    University of Illinois at Chicago is now Recruiting
    Start date Aug 2026→Nov 9, 2026 (now actual)
    Primary completion Aug 2029→Nov 2029
    Study completion Aug 2031→Nov 2031
    Eligibility 2 inclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedAbsolute neutrophil count ≥1.5x1095x10\^9 cell/L
    • EditedPlatelet count ≥100x109100x10\^9 cell/L
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedEfficacy of RiMO-301 when used in combination with radiotherapy and pembrolizumab as defined by clinicalmajor pathologic response rate (i.e., percentage of participants whose tumors shrink).Time frame: Treatment start until 12 months after the start of treatment → At surgical resection
    Secondary outcomes 1 removed, 1 description edited
    What changed in the outcomes
    • RemovedTo assess the rate of Major Pathological Response (MPR)Time frame: At surgical resection
    • DescriptionProgression-free survival rate as defined by the number of patients whose disease progresses since the start of treatment: how it is measured was reworded
    Sponsor University of Illinois at Chicago→University of Illinois Chicago
    Contact Study contact changed: j•••@uic.edu · •••1469→m•••@uic.edu · •••5112. See the current contact
    Title RiMO-HNC-NEO1: Phase 2 Study of RiMO-301 and Hypofractionated Radiotherapy With Pembrolizumab for the Neoadjuvant Treatment of Resectable, Locally Advanced Head-Neck Cancer
    + 3 other changes: verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07732634
Lead sponsor
University of Illinois Chicago
Collaborators
Coordination Pharmaceuticals, Inc.
Responsible party
Ameen Salahudeen (Principal Investigator, University of Illinois Chicago) — Principal investigator
First posted
Jul 29, 2026
Start date
Nov 9, 2026
Primary completion
Nov 2029 (estimated)
Completion
Nov 2031 (estimated)
Last update
Nov 16, 2026

Study contacts

Ameen Salahudeen, MD, PhD
Contact
ameen@uic.edu
(312) 355-1625
Meredith Russell
Contact
mrussel3@uic.edu
(312) 355-5112
Ameen Salahudeen, MD, PhD
principal investigator · Principal Investigator

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MOF Compound RiMO-301

Start the discussion